JNJ Earnings Preview: Solid Q4 Expected With Revenue Growth Above 5% in Sight
Other
Johnson & Johnson is expected to report solid Q4 earnings with adjusted EPS of $2.42 and sales of $24.1 billion. The company's multiple myeloma portfolio (Darzalex and Tecvayli) is projected to generate $25 billion by 2030, and Wall Street expects sustained revenue growth above 5%. However, Stelara faces biosimilar competition, and the company faces ongoing talc litigation. Analysts have raised price targets, with the stock up 43% in 2025.
Continue Reading